S. Söderlund

发表

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.

U. Olsson‐Strömberg, S. Mustjoki, J. Richter, 2020, Leukemia research.

The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

U. Olsson‐Strömberg, S. Mustjoki, M. Höglund, 2015, Molecular Cancer Therapeutics.

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

U. Olsson‐Strömberg, S. Mustjoki, B. Simonsson, 2013, PloS one.

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli.

U. Olsson‐Strömberg, S. Mustjoki, J. Richter, 2016, Leukemia research.

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

U. Olsson‐Strömberg, S. Mustjoki, M. Höglund, 2014, European journal of haematology.

Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis

Joakim S. Dahlin, G. Nilsson, J. Dahlin, 2018, bioRxiv.

Single-cell analysis reveals the KIT D816V mutation in hematopoietic stem and progenitor cells in systemic mastocytosis

G. Nilsson, J. Dahlin, M. Ekoff, 2018, bioRxiv.

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

U. Olsson‐Strömberg, S. Mustjoki, M. Höglund, 2022, The Journal of clinical investigation.

Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

U. Olsson‐Strömberg, J. Richter, A. Själander, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registry

U. Olsson‐Strömberg, L. Wennström, M. Höglund, 2021, British journal of haematology.

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

U. Olsson‐Strömberg, S. Mustjoki, M. Höglund, 2016, Leukemia.

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Martin C. Müller, U. Olsson‐Strömberg, S. Mustjoki, 2014 .

Disease Relapse After Tyrosine Kinase Inhibitor Treatment Discontinuation in Chronic Myeloid Leukaemia is Related to Both Low Number and Impaired Function of NK Cells

U. Olsson‐Strömberg, S. Mustjoki, S. Lehmann, 2014 .

Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study

U. Olsson‐Strömberg, S. Mustjoki, B. Gjertsen, 2021, European journal of haematology.

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI

U. Olsson‐Strömberg, S. Deneberg, J. Richter, 2021, Leukemia.

Disease Relapse After TKI Discontinuation In CML Is Related Both To Low Number and Impaired Function Of NK-Cells:Data From Euro-SKI

U. Olsson‐Strömberg, S. Mustjoki, S. Lehmann, 2013 .

Clinical and Immunological Studies in Chronic Myeloid Leukaemia

S. Söderlund, D. Milojkovic, Stina Söderlund, 2017 .

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

U. Olsson‐Strömberg, S. Mustjoki, J. Richter, 2019, Oncoimmunology.

In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia

U. Olsson‐Strömberg, J. Bergquist, J. Richter, 2016, Therapeutic drug monitoring.

Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register

U. Olsson‐Strömberg, M. Höglund, J. Richter, 2017, European journal of haematology.